spacer
home > ebr > summer 2004 > panacea in the pipeline - promising drug development efforts offer hope to cancer patients
PUBLICATIONS
European Biopharmaceutical Review

Panacea in the Pipeline - Promising Drug Development Efforts Offer Hope to Cancer Patients

The fight against cancer is one of the most arduously fought battles that the global pharmaceutical industry is engaged in. Cancer therapeutics R&D has evolved over the years in its attempt to find the cure for cancer in its many avatars. We might not know all about cancer and how to conquer it even today, but our knowledge about cancer and the therapeutic interventions is significant, given what it was even as recently as a decade ago. Basic and applied research in oncology has evolved by leaps and bounds, and there are more players with increasingly new approaches and a considerably growing number of pipeline drugs that are trying to tackle some of the biggest killer cancer types. Newer technologies and novel techniques have been deployed by the industry in this pitched battle; emerging and nascent disciplines like biotechnology and nanotechnology hold a lot of promise. This article takes a look at some of these efforts to understand what is in store for millions of hopeful cancer patients across the world.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Rajaram Sankaran, Industry Analyst with Frost & Sullivan's Technical Insights Division

Rajaram Sankaran is an Industry Analyst for Frost and Sullivan's Technical Insights Division, tracking advances in the pharmaceuticals, biotechnology, medical devices and diagnostic imaging industries. He is currently working on a research service entitled 'Nanomedicine - Global Developments and Growth Opportunities'. Previous experience includes assignments for Procter and Gamble, Roche Molecular Diagnostic Systems and two of India's top 10 pharmaceutical companies, Lupin Laboratories and Ranbaxy Laboratories. Rajaram graduated from Nagarjuna University in Physical Sciences and completed postgraduate studies in Management at IIFM, Bhopal.

spacer
Rajaram Sankaran
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Evolution Summit Press Release

“Many clinical trials today face delays because of difficulties in recruiting the required number of patients within the timeline. Sponsors need to look at other regions outside the US and Western Europe, that have access to a large pool of motivated patients, without compromising quality or anything else,” says Roman Hrynchuk, Chief Operating Officer, SanaClis. SanaClis was a solution provider at the Marcus Evans Evolution Summit March 2020.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement